INVO Fertility Posts 17% Revenue Growth, Clinic Profitability in Q2 2026 — INVO Fertility, Inc.

Event summary

Q2 2026 revenue increased 17% to $2.18 million, driven by full-quarter contribution from Family Beginnings acquisition and organic growth initiatives.
Clinic platform profitable on an Adjusted EBITDA basis before corporate expenses, generating $333,000 in Q2 2026.
Net income of $0.9 million in Q2 2026, compared to a net loss of $(3.6) million in the same period last year.
Birmingham clinic fully acquired in June 2026, converting from a joint venture to a wholly owned subsidiary.
Cash position improved to $3.7 million at June 30, 2026, up from $2.1 million at December 31, 2025.

The big picture

INVO Fertility's Q2 2026 results highlight its dual strategy of organic growth and targeted acquisitions in the fertility services sector. The company's focus on building a scalable platform with shared operational resources positions it to capitalize on the growing demand for assisted reproductive technology. The profitability of its clinic platform before corporate expenses underscores the underlying earnings power of its assets, while its robust acquisition pipeline suggests continued expansion opportunities.

What we're watching

Acquisition Strategy: Whether INVO Fertility can sustain its disciplined acquisition strategy of established, profitable fertility practices to drive further scale and profitability.
Organic Growth: The pace at which INVO Fertility can grow patient volumes and expand services across its existing clinic network to improve operating execution.
Financial Scalability: How the company's platform investments in operations, human resources, and finance will support a larger clinic network and improve consolidated Adjusted EBITDA.